Guidelines

ESCMID-EUCIC clinical guidelines on decolonization of multidrug-resistant Gram-negative bacteria carriers


1) Division of Infectious Diseases, Department of Internal Medicine I, Tübingen University Hospital, Germany
2) Infectious Diseases Section, Department of Diagnostic and Public Health, University of Verona, Verona, Italy
3) University of Groningen, University Medical Centre Groningen, Department of Critical Care, Groningen, the Netherlands
4) Adult Critical Care Medicine, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
5) Division of Infectious Diseases and Infection Control Programme, Geneva University Hospitals, Geneva, Switzerland
6) Faculty of Medicine, University of Geneva, Geneva, Switzerland
7) Department of Medical Microbiology, Leiden University Medical Centre, Leiden, the Netherlands
8) Infection Control Unit, Bichat-Claude Bernard Hospital, AP-HP, Paris, France
9) IAME, UMR 1137, DScID team, Université Paris Diderot, Sorbonne Paris Cité, Paris, France
10) European Committee on Infection Control (EUCIC), Basel, Switzerland
11) Institute for Infection Prevention and Hospital Epidemiology, Medical Centre, University of Freiburg, Faculty of Medicine, University of Freiburg, Germany
12) Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Istituto di Microbiologia, Rome, Italy
13) National Centre for Infection Control, Israel Ministry of Health, Israel
14) Sackler Faculty of Medicine, Tel Aviv University, Israel
15) Duke Clinical Research Institute, Duke University, Durham, NC, USA
16) Fondazione Policlinico Universitario A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Istituto di Microbiologia, Rome, Italy
17) National Centre for Infection Control, Israel Ministry of Health, Israel
18) Sackler Faculty of Medicine, Tel Aviv University, Israel
19) Institute for Infection Prevention and Hospital Epidemiology, Medical Centre, University of Freiburg, Faculty of Medicine, University of Freiburg, Germany

ABSTRACT

Scope: The aim of these guidelines is to provide recommendations for decolonizing regimens targeting multidrug-resistant Gram-negative bacteria (MDR-GNB) carriers in all settings.

Methods: These evidence-based guidelines were produced after a systematic review of published studies on decolonization interventions targeting the following MDR-GNB: third-generation cephalosporin-resistant Enterobacteriaceae (3GCephRE), carbapenem-resistant Enterobacteriaceae (CRE), aminoglycoside-resistant Enterobacteriaceae (AGRE), fluoroquinolone-resistant Enterobacteriaceae (FQRE), extremely drug-resistant Pseudomonas aeruginosa (XDRPA), carbapenem-resistant Acinetobacter baumannii (CRAB), and colistin-resistant Stenotrophomonas maltophilia (CRSM), and pan-drug-resistant Gram-negative organisms (PDRGNB). The recommendations are grouped by MDR-GNB species. Faecal microbiota transplantation has been discussed separately. Four types of outcomes were evaluated for each target MDR-GNB:(a) microbiological outcomes (carriage and eradication rates) at treatment end and at specific post-treatment time-points; (b) clinical outcomes (attributable and all-cause mortality and infection incidence) at the same time-points and length of hospital stay; (c) epidemiological outcomes (acquisition incidence, transmission and outbreaks); and (d) adverse events of decolonization (including resistance development). The level of evidence for and strength of each recommendation were defined according to the GRADE approach. Consensus of a multidisciplinary expert panel was reached through a nominal-group technique for the final list of recommendations.
Introduction

Multidrug-resistant Gram-negative bacteria (MDR-GNB), including third-generation cephalosporin-resistant Enterobacteriaceae (3GcRRE), carbapenem-resistant Enterobacteriaceae (CRE), Acinetobacter baumannii and Pseudomonas aeruginosa, are a critical priority for new antibiotic research and development according to the World Health Organization (WHO) [1]. One of the criteria weighed by WHO experts for prioritization of antibiotic-resistant bacteria was the availability of infection-control measures to reduce the spread of infection in community and healthcare settings. The most important criteria for prioritizing MDR-GNB were not only an empty pipeline and high attributable mortality in severe infections but also the dearth of effective infection control measures against these pathogens [2–5].

Decolonization has been an effective tool for reduction of morbidity and mortality from infections due to methicillin-resistant Staphylococcus aureus (MRSA) [6]. The assumption underlying decolonization in individuals colonized by MRSA is that colonization increases the subsequent infection risk. A systematic review of the link between colonization and subsequent MRSA infection that included ten observational studies and 1170 patients showed a four-fold increase in infection risk associated with colonization [6]. Previous studies showed that colonization with MDR-GNB increases the risk of infections [7–16]. A prospective observational study in 497 haematological patients identified previous colonization with extended-spectrum β-lactamase-producing Enterobacteriaceae (ESBL-E) as the most important risk factor for ESBL-E bloodstream infections [7]. Previous colonization with MDR-GNB also increases infection risk in transplant and intensive care unit (ICU) patients and those undergoing major abdominal surgery [8–16]. Several factors have been associated with carriage phenotype: species and susceptibility pattern [17], host features, antibiotic exposure duration and type, and the extent of contact with healthcare environments [18–22].

The most extensive experience in MDR-GNB decolonization is with selective digestive decontamination (SDD) in ICU patients, but studies have shown conflicting results [12,13,23–26]. In randomized controlled trials (RCTs) performed in ICUs with low MDR-GNB endemicity, SDD significantly reduced infections and mortality with limited impact on new resistance selection [26–31]. Recently a study performed in a high-endemicity ICU in Spain over 4 years showed that SDD reduced MDR-GNB infections with a non-significant increase in resistance to decolonizing agents [32]. Major limitations of these studies are heterogeneity in patient case mix, ward colonization pressure, and agents combined in the decolonization protocols.

The most recently developed guidelines on prevention of CRE spread in hospitalized patients, evaluating studies up to 2014, do not advise for or against decolonization because of a very low level of evidence [2–4]. The objective of these guidelines is to provide evidence-based recommendations for decolonization of MDR-GNB carriers, irrespective of age, co-morbidities and setting. Specifically, we address the following questions:

(a) What decolonization regimens have been evaluated for patients colonized with the target MDR-GNB?
(b) Do we recommend decolonization for patients colonized with the target MDR-GNB?
(c) What is the regimen of choice for patients colonized with the target MDR-GNB?

Expected users in hospital and community healthcare settings include infection control specialists, healthcare providers (clinical medical, nursing and paramedical staff) and policy-makers.

Methods

These guidelines were developed by a multidisciplinary group of experts, selected by the European Committee of Infection Control (EUCIC) according to the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) recommendations for developing guidance documents. This expert panel reviewed the articles and discussed evidence-based tables, evidence certainty classification, and recommendation strength in two meetings at ECCMID 2017 and 2018, and by teleconference. Consensus of panel members for the final list of recommendations was reached through a nominal-group technique.

Literature search and data extraction

We began the guidelines development process with a systematic review of the published literature. The review protocol was registered on the International Prospective Register of Systematic Reviews (PROSPERO) (https://doi.org/10.15124/CRD42017082729) and is available in full on the PROSPERO website (https://www.crd.york.ac.uk/prospero/display_record.php?RecordID¼82729). The protocol followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement [33]. We included all studies evaluating any decolonization regimen targeting patients colonized with MDR-GNB. Articles were identified through computerized literature searches using PubMed, the Cochrane Database of Systematic Reviews, the Cochrane Central Register of Controlled Trials and Web of Science. The search was restricted to full-text articles published in English without restriction of publication year. A combination of Medical Subject Headings and equivalent terms was used in the search strategy (see Supplementary material, Appendix S1). Literature searches for each target organism were performed between 9 and 16 August 2017. Two independent reviewers performed a two-stage selection process. First, abstracts were screened against eligibility criteria and duplicate and irrelevant documents were excluded. We excluded studies involving universal decolonization (decolonization of all carriers, irrespective of age, co-morbidities and setting). Specifically, we address the following questions:

(a) What decolonization regimens have been evaluated for patients colonized with the target MDR-GNB?
(b) Do we recommend decolonization for patients colonized with the target MDR-GNB?
(c) What is the regimen of choice for patients colonized with the target MDR-GNB?

Expected users in hospital and community healthcare settings include infection control specialists, healthcare providers (clinical medical, nursing and paramedical staff) and policy-makers.

Recommendations: The panel does not recommend routine decolonization of 3GcRRE and CRE carriers. Evidence is currently insufficient to provide recommendations for or against any intervention in patients colonized with ACRE, CoRGNB, CRAB, CRSM, FQRE, PDRGNB and XDRPA. On the basis of the limited evidence of increased risk of CRE infections in immunocompromised carriers, the panel suggests designing high-quality prospective clinical studies to assess the risk of CRE infections in immunocompromised patients. These trials should include monitoring of development of resistance to decolonizing agents during treatment using stool cultures and antimicrobial susceptibility results according to the EUCAST clinical breakpoints. E. Tacconelli. Clin Microbiol Infect 2019;25:807–817 © 2019 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
patients without previous screening), preoperative surgical prophylaxis, environmental decolonization, and in vitro and animal studies. Next, full-text articles were assessed, study data (design, population, target bacteria, intervention, comparison, treatment duration and outcomes) were extracted from eligible articles, and references were screened on title and abstract for further inclusion. At both stages each article was reviewed by two reviewers, and any discrepancies were resolved through discussion with a third reviewer (see flow charts in Supplementary material, Appendix S2).

A population/participant, intervention, comparator/control, outcome, known as PICO, framework was developed. Population: any patient of any age in any community or healthcare setting with any screening sample yielding one of the following MDR-GNB were included: 3GCephRE, CRE, aminoglycoside-resistant Enterobacteriaceae (AGRE), fluoroquinolone-resistant Enterobacteriaceae (FQRE), extremely drug-resistant Pseudomonas aeruginosa (susceptibility maintained to up to two antibiotic classes: aminoglycosides, anti-pseudomonal carbapenem, antipseudomonal cefepime, antipseudomonal fluoroquinolone, antipseudomonal penicillin + β-lactamase inhibitor, monobactam, phosphonic acid, polymyxin [34]), carbapenem-resistant Acinetobacter baumannii (CRAB), colistin-resistant Stenotrophomonas maltophilia, colistin-resistant Gram-negative organisms, pan-drug-resistant (non-susceptible to all tested agents) Gram-negative organisms [34]. Intervention: decolonization therapy, defined as any measure that leads to loss of detectable MDR-GNB carriage at any site. Decolonizing regimens included topical agents, systemic therapy, antibiotic inhaled therapy, natural compounds, bacteriophage therapy, alternative treatments, and novel regimens undergoing trials. Controls: patients receiving no intervention (spontaneous decolonization) or a second decolonization measure were included. Outcomes: four outcome types—microbiological, clinical, epidemiological and adverse events—were evaluated for each target organism. The microbiological outcomes of carriage rate or eradication rate were assessed at different time-points (at treatment end and at 7 days, 1 month, 6 months and 1 year after treatment). Clinical outcomes included attributable and all-cause mortality and infection incidence at the same time-points, and length of hospital stay. Epidemiological outcomes included acquisition incidence, transmission, and outbreaks in hospitals, healthcare settings or the community. Assessment of decolonization adverse events included the investigation of resistance development. Because of the expected paucity of RCTs and non-randomized controlled trials, uncontrolled studies were also reviewed.

Quality assessment

The quality assessment was performed using the Effective Practice and Organization of Care guidelines for RCTs [35] and the Newcastle–Ottawa Scale for non-randomized controlled trials [36]. Each article was assessed by two reviewers, and discrepancies were resolved by a third reviewer. Evidence certainty of controlled studies was classified as high, moderate, low or very low, and recommendation strength was classified as strong or conditional according to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system [37]. The panel also assessed recommendations for research and possible conditional use in restricted trials and good practice points. The Supplementary material (Appendix S2) gives a detailed description of the GRADE approach, grades of evidence and determinants of quality.

Results and recommendations

The guidelines are organized by target organism. Each section reports the main characteristics of controlled studies, a summary of the evidence, and a recommendation graded according to the available evidence. Flow charts of assessed studies are included in the Supplementary material (Appendix S2). No articles were found for extremely drug-resistant Pseudomonas aeruginosa, co-trimoxazole-resistant Stenotrophomonas maltophilia, colistin-resistant Gram-negative organisms or pan-drug-resistant Gram-negative organisms. Twelve studies were included for 3GCephRE, 18 for CRE, six for CRAB, one for FQRE and one for AGRE. Of these studies, two 3GCephRE studies and seven CRE studies focused on faecal microbiota transplantation (FMT) are discussed separately at the end of this section. Tables 1–3 provide details of study designs and results.

Third-generation cephalosporin-resistant Enterobacteriaceae

Study characteristics

The ten studies were performed in Europe (nine studies) and the USA (one study); two RCTs [38,39], two prospective cohort studies [40,41], one uncontrolled nested post hoc analysis of a cluster-randomized study with additional hospital data [42], and five case series without comparators [43–47]. Only one study had a multicentre design [42]. Two studies evaluated hospital patients [38,39]; five evaluated ICU patients [41–43,45,47]; one evaluated liver transplanted patients [46]; two studied outpatients [39,44], and two studies were conducted in paediatric wards [43,45]. Four studies were performed during a 3GCephRE outbreak [41,43,46,47], three studies were performed in healthcare centres reporting endemic 3GCephRE [40,44,45], and three studies did not specify local epidemiology [38–40]. All studies performed rectal screening [38–47], four included urine cultures [38,39,41,45], and two included respiratory tract cultures [43,45].

Huttner et al. conducted an RCT to assess the efficacy of oral non-absorbable antibiotics on rectal ESBL-E carriage in hospital patients [38]. Fifty-eight patients were allocated to either placebo or oral colistin sulphate (50 mg (salt) four times daily) and neomycin sulphate (250 mg (salt) four times daily) for 10 days (plus nitrofurantoin for 5 days in the event of urine detection) [38]. Jonsson et al. assessed the role of anti-ESBL immunoglobulin Y chicken antibodies in ESBL-E faecal carriage eradication, randomizing 24 outpatients to either active treatment or placebo [39]. The RCT was discontinued before completion because of high drop-out. In an 8-year prospective cohort study, Buehlmann et al. enrolled 35 asymptomatic ESBL-E carriers and treated with chlorhexidine mouth rinse for 4 days for throat colonization, oral paromomycin for 4 days for rectal colonization, or oral nitrofurantoin or fosfomycin (single dose) or ciprofloxacin or ciprofloxacin for 5 days for urinary colonization [40]. The course was repeated in patients with persistent ESBL-E carriage. Decré et al. performed a prospective cohort trial of 404 patients colonized or infected with ESBL-producing Klebsiella pneumoniae and compared universal with target SDD using oral erythromycin (1 g twice daily) and colistin sulphate (6 million units twice daily) [41]. Decolonization regimens in the six uncontrolled studies differed widely: the most common agent was oral colistin alone [44] or combined with either oral aminoglycosides (neomycin, amikacin, or tobramycin) [42,43,45,47], erythromycin [47], rifaximin [44], or norfloxacin [46]. Treatment duration, when reported, ranged from 5 to 28 days. Oostdijk et al. conducted a nested post hoc analysis without comparator of a cluster-randomized multicentre trial in 13 Dutch ICUs. Fifty patients received oropharyngeal application of a paste containing colistin, tobramycin and amphotericin B, each at a concentration of 2%, and a 10-mL suspension containing 100 mg of colistin, 80 mg of tobramycin, and 500 mg of amphotericin B via a nasogastric tube. Topical antibiotics were applied four times daily until discharge from ICU. In addition, intravenous cefotaxime (1000 mg, every 6 h) was administered for the first 4 days. Rectal carriage of 3GCephRE and AGRE was determined at admission and twice weekly during the ICU stay [42].
### Table 1
Characteristics of 27 included studies (sorted by study design)

<table>
<thead>
<tr>
<th>Author, year of publication [ref.]</th>
<th>Study design</th>
<th>Population</th>
<th>Target bacteria</th>
<th>Intervention</th>
<th>Comparison</th>
<th>Treatment duration</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saidel-Odes, 2012 [51]</td>
<td>RCT</td>
<td>Mixed population</td>
<td>CRE</td>
<td>Gentamicin (80 mg) qid + colistin (1 MIU)</td>
<td>Placebo</td>
<td>7 days</td>
</tr>
<tr>
<td>Nouvenne, 2015 [52]</td>
<td>RCT</td>
<td>Mixed population</td>
<td>CRE</td>
<td>High-dose probiotics + psyllium</td>
<td>Standard care</td>
<td>14 days</td>
</tr>
<tr>
<td>Huttner, 2013 [38]</td>
<td>RCT</td>
<td>Mixed population</td>
<td>CRE</td>
<td>Gentamicin sulphate (80 mg) qid + tobramycin (80 mg) qid</td>
<td>Placebo</td>
<td>10 days</td>
</tr>
<tr>
<td>Jonsson, 2015 [39]</td>
<td>RCT</td>
<td>Mixed population</td>
<td>CRE</td>
<td>Gentamicin sulphate (1.26 MIU) qid</td>
<td>Placebo</td>
<td>21 days</td>
</tr>
<tr>
<td>Tannock, 2011 [64]</td>
<td>RCT</td>
<td>Long-term care facility residents</td>
<td>CRE</td>
<td>Probiotic strain E. coli Nissle 1917</td>
<td>Placebo</td>
<td>5 weeks</td>
</tr>
<tr>
<td>Oren, 2013 [53]</td>
<td>Semi-randomized trial</td>
<td>Mixed population</td>
<td>CRE</td>
<td>Gentamicin (80 mg) qid or colistin (2 MIU) qid</td>
<td>Spontaneous colonosclerosis</td>
<td>Up to eradication (maximum, 60 days)</td>
</tr>
<tr>
<td>Buehlmann, 2011 [40]</td>
<td>Prospective cohort</td>
<td>Mixed population</td>
<td>CRE</td>
<td>Gentamicin sulphate (80 mg) qid + tobramycin (80 mg) qid</td>
<td>Interrupted colonosclerosis</td>
<td>4–5 days; repeated courses until achievement of eradication</td>
</tr>
<tr>
<td>Decré, 1998 [41]</td>
<td>Prospective cohort</td>
<td>ICU</td>
<td>CRE</td>
<td>Erythromycin (1 g) bid + polymixin E (6 MIU) bid</td>
<td>Standard care</td>
<td>Not reported</td>
</tr>
<tr>
<td>Borer, 2007 [65]</td>
<td>Prospective cohort</td>
<td>ICU</td>
<td>CRAB</td>
<td>Topical 4% chlorhexidine, one full body wash daily</td>
<td>Standard care</td>
<td>Not reported</td>
</tr>
<tr>
<td>Machua, 2016 [55]</td>
<td>Retrospective cohort</td>
<td>Mixed population</td>
<td>CRE</td>
<td>Gentamicin (80 mg) qid or streptomycin (80 mg) tid + neomycin (40 mg) tid</td>
<td>Standard care</td>
<td>14 days</td>
</tr>
<tr>
<td>Lubbert, 2013 [34]</td>
<td>Retrospective cohort</td>
<td>ICU</td>
<td>CRE</td>
<td>Gentamicin sulphate (80 mg) qid + tobramycin (80 mg) qid</td>
<td>Standard care</td>
<td>7 days</td>
</tr>
<tr>
<td>Agusti, 2002 [66]</td>
<td>Prospective cohort</td>
<td>ICU</td>
<td>CRAB</td>
<td>Gentamicin sulphate (80 mg) qid + tobramycin (80 mg) qid</td>
<td>Standard care</td>
<td>Variable (mean, 35.8 days)</td>
</tr>
<tr>
<td>Chen, 2014 [67]</td>
<td>Case–control</td>
<td>Mixed population</td>
<td>CRAB</td>
<td>Inhaled colistin (2 MIU/160 mg) bid</td>
<td>Standard care</td>
<td>Variable (10.9 ± 3.6 days)</td>
</tr>
<tr>
<td>Kuo, 2012 [68]</td>
<td>Case–control</td>
<td>Mixed population</td>
<td>CRAB</td>
<td>Inhaled colistin (2 MIU/160 mg) bid</td>
<td>Standard care</td>
<td>Up to ICU discharge</td>
</tr>
<tr>
<td>Oostdijk, 2012 [42]</td>
<td>Nested post hoc analysis</td>
<td>ICU</td>
<td>CRE</td>
<td>Colistin (2 MIU) qid + tobramycin (80 mg) qid</td>
<td>NA</td>
<td>5 days</td>
</tr>
<tr>
<td>Gutierrez-Urbon, 2015 [43]</td>
<td>Case series</td>
<td>Paediatric ICU</td>
<td>CRE</td>
<td>Colistin standard dose (1 MIU) or high dose (2 MIU) qid</td>
<td>NA</td>
<td>4 weeks</td>
</tr>
<tr>
<td>Rieg, 2015 [44]</td>
<td>Case series</td>
<td>Mixed population</td>
<td>CRE</td>
<td>Colistin standard dose (1 MIU) or high dose (2 MIU) qid</td>
<td>NA</td>
<td>Not reported</td>
</tr>
<tr>
<td>Abecasis, 2011 [45]</td>
<td>Case series</td>
<td>Paediatric ICU</td>
<td>CRE</td>
<td>Colistin standard dose (1 MIU) or high dose (2 MIU) qid</td>
<td>NA</td>
<td>Not reported</td>
</tr>
<tr>
<td>Paterson, 2001 [46]</td>
<td>Case series</td>
<td>SOT</td>
<td>CRAB</td>
<td>Norfloxacine (400 mg) bid</td>
<td>NA</td>
<td>5 days</td>
</tr>
<tr>
<td>Troché, 2005 [47]</td>
<td>Case series</td>
<td>ICU</td>
<td>CRE</td>
<td>Colistin sulphate (1.5 MIU) qid</td>
<td>NA</td>
<td>Not reported</td>
</tr>
<tr>
<td>De Rosa, 2016 [56]</td>
<td>Case series</td>
<td>Haematological malignancy</td>
<td>CRE</td>
<td>Gentamicin (80 mg)</td>
<td>NA</td>
<td>Variable (mean, 5 days)</td>
</tr>
<tr>
<td>Tascini, 2014 [59]</td>
<td>Case series</td>
<td>Mixed population</td>
<td>CRE</td>
<td>Gentamicin (80 mg)</td>
<td>NA</td>
<td>&gt;7 days, variable (mean, 16 days)</td>
</tr>
<tr>
<td>Zuckerman, 2011 [57]</td>
<td>Case series</td>
<td>Haematological malignancy</td>
<td>CRE</td>
<td>Gentamicin (80 mg)</td>
<td>NA</td>
<td>Up to eradication (mean, 27 days; range, 7–90 days)</td>
</tr>
<tr>
<td>Lambelet, 2017 [58]</td>
<td>Case series</td>
<td>Haematological malignancy</td>
<td>CRE</td>
<td>Gentamicin (80 mg)</td>
<td>NA</td>
<td>Up to eradication (range, 7–25 days)</td>
</tr>
<tr>
<td>Gray, 2016 [69]</td>
<td>Case series</td>
<td>Mixed population</td>
<td>CRAB</td>
<td>Chlorhexidine gluconate-impregnated wipes 2x daily</td>
<td>NA</td>
<td>Not reported</td>
</tr>
<tr>
<td>Hsieh, 2014 [70]</td>
<td>Case series</td>
<td>Mixed population</td>
<td>CRAB</td>
<td>Gentamicin sulphate (2 MIU) bid</td>
<td>NA</td>
<td>Variable (range, 11–13.5 days)</td>
</tr>
<tr>
<td>Kronman, 2014 [61]</td>
<td>Case report</td>
<td>Haematological malignancy</td>
<td>CRE</td>
<td>Gentamicin + colistin (doses not specified)</td>
<td>NA</td>
<td>10 days</td>
</tr>
<tr>
<td>Brink, 2013 [60]</td>
<td>Case report</td>
<td>Haematological malignancy</td>
<td>CRE</td>
<td>Gentamicin + tobramycin (doses not specified)</td>
<td>NA</td>
<td>Not reported</td>
</tr>
</tbody>
</table>

Abbreviations: AGRE, aminoglycoside-resistant Enterobacteriaceae; bid, twice daily; CRAB, carbapenem-resistant Acinetobacter baumannii; CRE, carbapenem-resistant Enterobacteriaceae; ESBL, extended-spectrum β-lactamase; FQRE, fluoroquinolone-resistant Enterobacteriaceae; ICU, intensive care unit; IgG, immunoglobulin G; NA, not applicable; qid, four times daily; RCT, randomized controlled trial; SOT, solid organ transplant; 3GcephRE, third-generation cephalosporin-resistant Enterobacteriaceae; tid, thrice daily.
Clinical outcomes

Two case series [43,45] and the nested post hoc analysis [42] included clinical outcomes (all-cause mortality at treatment end or length of stay) — Abdasis et al. reported a 20.5% (8/39) mortality rate [45] and Gutierrez-Urbon et al. reported no deaths [43]. Oostdijk et al. observed a median ICU stay of 12 days (range 3–77; interquartile range [IQR], 10) for 3GcephRE-colonized patients and 13 days (range 3–77; IQR, 11) for decolonized patients [42].

Microbiological outcomes

One RCT [38], one prospective cohort study [40] and all studies without comparator [42–47] included microbiological outcomes (carriage rate or eradication rate). Huttner et al. observed a significantly lower rectal carriage rate in the treatment group than in the placebo group at treatment end (32.0% (8/25) versus 76.9% (20/26); p 0.001), but the effect was lost at 7 days post-treatment (66.7% (18/27) versus 68% (17/25); p 0.92) and at 28 days post-treatment (51.9% (14/27) versus 37% (10/27); p 0.28) [38]. Buehlmann et al. showed that repeated decolonization significantly improved eradication rate at treatment end (88.9% (16/18) versus 41.1% (7/17); p 0.007) [40]. The studies without comparator reported decolonization rates at treatment end ranging from no effect to 100% [42–47].

Epidemiological outcomes

One prospective cohort study [41] evaluated the impact of decolonization regimen on epidemiological outcomes (incidence of acquired colonization and acquired infections). No significant difference from the historical control group was observed in the incidence of acquired 3GcephRE colonization in the digestive tract (10% versus 9.1%) or in the incidence of acquired infections (7.5% versus 3.6%).

Adverse events

Resistance development was assessed in one RCT and one uncontrolled study [38,42]. Huttner et al. observed no statistically significant changes in the colistin or neomycin MICs between baseline and final ESBL-E isolates in the treatment group [38]. Oostdijk et al. found no association with increased resistance over time when eradication failed [42]. Adverse events were evaluated in two RCTs [38,39] and one study without comparator [43]. In the Huttner et al. trial, 7/27 (25.9%) patients in the treatment group versus 2/25 (6.9%) patients in the placebo group (p 0.05) experienced liquid stool during follow up [38], whereas in the Jonsson study the proportion of participants who reported various adverse events was similar between the treatment and the placebo groups (58% versus 42%) [39].

Other relevant outcomes

A significantly lower rectal carriage rate was observed by Huttner et al. on day 6 of treatment (9/26 (34.6%) versus 19/22 (86.3%); p < 0.001) [38].

Evidence evaluation

Evidence was of moderate [38] and very low [40] certainty for microbiological eradication at treatment end, low for microbiological eradication at 7 days and 28 days post-treatment [38] and for resistance development [38,39].

Recommendation

The panel does not recommend routine decolonization of 3GcephRE carriers.

Grading: conditional recommendation against the intervention.

Research and possibly conditional use in restricted trials

On the basis of the limited evidence of temporary effectiveness of decolonization [38,40] and the increased risk of developing ESBL-E bloodstream infections in neutropenic colonized patients [7,48,49], the panel suggests designing clinical trials of decolonization with oral colistin sulphate (50 mg (salt) four times daily) and neomycin sulphate (250 mg (salt) four times daily) to temporarily suppress 3GcephRE carriage in patients with severe neutropenia (absolute neutrophil count <500 µL). These trials should include careful monitoring for development of resistance to neomycin or colistin during decolonization using stool cultures and antimicrobial susceptibility results according to the European Committee on Antimicrobial Susceptibility Testing (EUCAST) clinical breakpoints [50].

Carbapenem-resistant Enterobacteriaceae

Study characteristics

The 11 studies were performed in Europe (6), Israel (3), South Africa (1) and the USA (1): two RCTs [51,52], one semi-randomized control trial [53], two retrospective cohort studies [54,55], and six case series and case reports without comparators [56–61]. Two studies had a multicentre design [55,59]. Six studies evaluated hospital inpatients [51–53,55,59,60], one assessed ICU patients [54], and four evaluated haematological patients [56,57,59,61]. Four studies were performed during a CRE outbreak [54,55,57,60]. Seven studies did not specify local epidemiology [51,53,55,56,58,59,61]. Rectal carriage testing was performed in all studies, and urinary carriage and respiratory tract colonization were assessed in one study each [51,54].

Saidel-Odes et al. conducted an RCT to test the efficacy of intestinal decontamination on CRE carriage. Forty patients were randomized to receive either placebo or colistin (1 MU four times daily) and gentamicin sulphate (80 mg four times daily) for 7 days [51]. Nouvenne et al. performed an RCT in 32 patients assessing the role of high-dose probiotics in CRE faecal carriage eradication. The patients were randomly assigned to either high-dose probiotics and psyllium for 14 days or standard care [52]. Oren et al. evaluated 50 patients treated with one of three regimens: colistin sulphate (2 MU four times daily), gentamicin sulphate (80 mg four times daily), or both [53]. The patients were assigned to antibiotic regimens either according to susceptibility or randomly (for carriers of strains susceptible to both colistin and gentamicin). Patients undergoing treatment were compared with controls (102 patients) for eradication and clinical outcomes. Machuca et al. analysed a retrospective cohort of 77 patients using two regimens: gentamicin solution (80 mg four times daily) or streptomycin sulphate (80 mg three times daily) and neomycin (40 mg three times daily) for 14 days [55]. Lubbert et al. analysed a retrospective cohort of 16 ICU patients treated for 7 days with colistin sulphate (1 MU four times daily) and gentamicin sulphate (80 mg four times daily) [54].

Clinical outcomes

All controlled studies [51–55] and four studies without comparator [56–60] included clinical outcomes (all-cause and attributable mortality, CRE-related infection incidence or length of hospital stay). Machuca et al. reported a significant reduction in all-cause mortality associated with the use of decolonization therapy at 6 months after treatment end (25% versus 54%; hazard ratio (HR) 0.18; 95% CI 0.06–0.55) [55]. Oren et al. observed a reduction in all-cause mortality without impact on attributable mortality during the follow-up period (timing not specified) (22% (11/50) versus 53% (54/102); p < 0.001) [53]. Nouvenne et al. and Lubbert et al. did not
find any significant effect of decolonization treatment on mortality during hospitalization [52,54].

Machuca et al. reported a significant reduction in the CRE-related infection incidence at 6 months follow up (4.5% [2/44] versus 39.4% [13/33]; p < 0.001) [55]. Univariate analysis demonstrated a lower risk of carbapenemase-producing K. pneumoniae infections in the follow-up period associated with decolonization (HR 0.14; 95% CI 0.02–0.83). Only gentamicin was significantly associated with infection rate reduction in the analysis stratified by treatment (crude HR 0.86; 95% CI 0.008–0.94). Two studies analysing the effect of decolonization on length of hospital stay found no difference between treated and untreated patients [51,54].

**Microbiological outcomes**

All controlled studies [51–55] and all studies without comparator [56–61] included microbiological outcomes (carriage rate or eradication rate). In the RCT by Saidel-Odes et al., significant carriage rate reduction was observed 7 days post-treatment (38.8% versus 83.9%; OR 0.13; 95% CI 0.02–0.74; p < 0.0016), but the effect was lost at 28 days, resulting in a non-significant difference between the two groups (41.5% versus 66.7%) [51]. In the RCT by Nouvenne et al., significant reduction in carriage rate during hospitalization was associated with administration of high-dose probiotics (p 0.009) [52]. In the semi-randomized trial by Oren et al., the eradication rate during follow up was significantly higher in the intervention group (56% [22/50] versus 7% [7/102]; p < 0.001) [53]. The retrospective cohort study by Machuca et al. found a significant difference in decolonization rate between the control and treated groups (51.1% versus 91%; p < 0.001) at 180 days post-treatment (HR 4.06; 95% CI 1.06–15.6) [55]. When stratified by treatment regimen, gentamicin was associated with a significantly higher microbiological success rate (HR 5.67; 95% CI 1.33–24.1). The other regimen (streptomycin and neomycin combination) showed no significant association. The retrospective cohort study by Lubbert et al. showed no significant difference in the decolonization rate between the two groups [54].

### Table 2

**Microbiological outcomes**

<table>
<thead>
<tr>
<th>Author, year of publication [ref.]</th>
<th>Target bacteria</th>
<th>Sample size</th>
<th>Time-point</th>
<th>Eradication rate</th>
<th>95% CI</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saidel-Odes, 2012 [51]</td>
<td>CRE</td>
<td>Intervention 20; control 20</td>
<td>7 days after EoT</td>
<td>OR, 0.13</td>
<td>0.02–0.74</td>
<td>0.0016</td>
</tr>
<tr>
<td>Nouvenne, 2015 [52]</td>
<td>CRE</td>
<td>Intervention 18; control 14</td>
<td>28 days after EoT</td>
<td>58.3% vs. 33.3%</td>
<td>NA</td>
<td>NS</td>
</tr>
<tr>
<td>Hutner, 2013 [38]</td>
<td>3GCephRE ESBL producer</td>
<td>Intervention 27; control 27</td>
<td>EoT</td>
<td>NA</td>
<td>NA</td>
<td>0.001</td>
</tr>
<tr>
<td>Oren, 2013 [53]</td>
<td>CRE</td>
<td>Intervention 36; control 33</td>
<td>5 weeks after EoT</td>
<td>23% vs. 42%</td>
<td>NA</td>
<td>NS</td>
</tr>
<tr>
<td>Buehmann, 2011 [40]</td>
<td>3GCephRE ESBL producer</td>
<td>Intervention 18; control 17</td>
<td>EoT</td>
<td>OR, 11.42</td>
<td>1.6–102.6</td>
<td>NA</td>
</tr>
<tr>
<td>Machuca, 2016 [55]</td>
<td>CRE</td>
<td>Intervention 44; control 33</td>
<td>6 months after EoT</td>
<td>aHR, 4.06</td>
<td>1.06–15.6</td>
<td>0.04</td>
</tr>
<tr>
<td>Agusti, 2002 [66]</td>
<td>CRAB</td>
<td>Intervention 33; control 21</td>
<td>EoT</td>
<td>57% vs. 83%</td>
<td>NA</td>
<td>NS</td>
</tr>
<tr>
<td>Chen, 2014 [57]</td>
<td>CRAB</td>
<td>Intervention 81; control 54</td>
<td>14 days after EoT</td>
<td>54% vs. 30%</td>
<td>NA</td>
<td>0.005</td>
</tr>
<tr>
<td>Kuo, 2012 [68]</td>
<td>AGRE</td>
<td>Intervention 39; control 39</td>
<td>14 days after EoT</td>
<td>85% vs. 10%</td>
<td>NA</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Oostdijk, 2012 [42]</td>
<td>3GCephRE</td>
<td>Intervention 77; control NA</td>
<td>EoT</td>
<td>NA</td>
<td>73%</td>
<td>NA</td>
</tr>
<tr>
<td>Gutierrez-Urbon, 2015 [43]</td>
<td>3GCephRE ESBL producer</td>
<td>Intervention 6; control NA</td>
<td>EoT</td>
<td>NA</td>
<td>0%</td>
<td>NA</td>
</tr>
<tr>
<td>Rieg, 2015 [44]</td>
<td>3GCephRE ESBL producer</td>
<td>Intervention 45; control NA</td>
<td>14 days after EoT</td>
<td>Colistin SD 39%; colistin HD 25%; rifaximin 60%</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Abecasis, 2011 [45]</td>
<td>3GCephRE ESBL producer</td>
<td>Intervention 39; control NA</td>
<td>EoT</td>
<td>77%</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Paterson, 2001 [46]</td>
<td>3GCephRE ESBL producer</td>
<td>Intervention 9; control NA</td>
<td>EoT</td>
<td>100%</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Troche, 2005 [47]</td>
<td>3GCephRE ESBL producer</td>
<td>Intervention 37; control NA</td>
<td>EoT</td>
<td>46%</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>De Rosa, 2016 [56]</td>
<td>CRE</td>
<td>Intervention 8; control NA</td>
<td>NA</td>
<td>25%</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Tascini, 2014 [59]</td>
<td>CRE</td>
<td>Intervention 50; control NA</td>
<td>NA</td>
<td>68%</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Zuckerman, 2011 [57]</td>
<td>CRE</td>
<td>Intervention 15; control NA</td>
<td>NA</td>
<td>66%</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Lambelet, 2017 [58]</td>
<td>CRE</td>
<td>Intervention 14; control NA</td>
<td>NA</td>
<td>71%</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Hseih, 2014 [70]</td>
<td>CRAB</td>
<td>Intervention: - Colonized group 61; - Pneumonia group 57</td>
<td>Control NA</td>
<td>NA</td>
<td>72%</td>
<td>79%</td>
</tr>
<tr>
<td>Kronman, 2014 [61]</td>
<td>CRE</td>
<td>Intervention 1; control NA</td>
<td>28 days after EoT</td>
<td>100%</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Brink, 2013 [60]</td>
<td>CRE</td>
<td>Intervention 1; control NA</td>
<td>EoT</td>
<td>%</td>
<td>NA</td>
<td>NA</td>
</tr>
</tbody>
</table>

Abbreviation: aHR, adjust hazard ratio; CRAB, carbapenem-resistant Acinetobacter baumannii; CRE, carbapenem-resistant Enterobacteriaceae; ESBL, extended-spectrum β-lactamase; EoT, end of treatment; FQRE, fluoroquinolone-resistant Enterobacteriaceae; HD, high dose; NA, not applicable; NS, not significant; OR, odds ratio; SD, standard dose; 3GCephRE, third-generation cephalosporin-resistant Enterobacteriaceae.
### Table 3

<table>
<thead>
<tr>
<th>Author, year of publication [ref.]</th>
<th>Target bacteria</th>
<th>Sample size</th>
<th>Clinical outcome</th>
<th>Time-point</th>
<th>Effect size</th>
<th>95% CI</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nouvenne, 2015 [52]</td>
<td>CRE</td>
<td>Intervention 18; control 14</td>
<td>All-cause mortality</td>
<td>NA</td>
<td>31% vs. 12%</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Oren, 2013 [53]</td>
<td>CRE</td>
<td>Intervention 50; control 102</td>
<td>All-cause mortality</td>
<td>NA</td>
<td>22% vs. 53%</td>
<td>NA</td>
<td>NS</td>
</tr>
<tr>
<td>Machuca, 2016 [55]</td>
<td>Colistin-resistant CRE</td>
<td>Intervention 44; control 33</td>
<td>All-cause mortality</td>
<td>6 months after EoT</td>
<td>aHR, 0.18</td>
<td>0.06-0.55</td>
<td>0.003</td>
</tr>
<tr>
<td>Lubbert, 2013 [54]</td>
<td>CRE</td>
<td>Intervention 16; control 76</td>
<td>All-cause mortality</td>
<td>6 months after EoT</td>
<td>aHR, 0.14</td>
<td>0.02-0.84</td>
<td>0.03</td>
</tr>
<tr>
<td>Agusti, 2002 [66]</td>
<td>CRAB</td>
<td>Intervention 33; control 21</td>
<td>All-cause mortality</td>
<td>EoT</td>
<td>36% vs. 45%</td>
<td>NA</td>
<td>NS</td>
</tr>
<tr>
<td>Chen, 2014 [67]</td>
<td>CRAB</td>
<td>Intervention 81; control 54</td>
<td>All-cause mortality</td>
<td>EoT</td>
<td>14% vs. 16%</td>
<td>NA</td>
<td>NS</td>
</tr>
<tr>
<td>Kuo, 2012 [68]</td>
<td>CRAB</td>
<td>Intervention 39; control 39</td>
<td>All-cause mortality</td>
<td>EoT</td>
<td>9% vs. 10%</td>
<td>NA</td>
<td>NS</td>
</tr>
<tr>
<td>Gutierrez-Urbon, 2015 [43]</td>
<td>3GcephRE ESBL producer</td>
<td>Intervention 6; control NA</td>
<td>All-cause mortality</td>
<td>EoT</td>
<td>31% vs. 41%</td>
<td>NA</td>
<td>NS</td>
</tr>
<tr>
<td>Abecasis, 2011 [45]</td>
<td>3GcephRE ESBL producer</td>
<td>Intervention 39; control NA</td>
<td>All-cause mortality</td>
<td>EoT</td>
<td>21%</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>De Rosa, 2016 [56]</td>
<td>CRE</td>
<td>Intervention 8; control NA</td>
<td>Incidence of infection</td>
<td>6 months after EoT</td>
<td>37%</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Tascini, 2014 [59]</td>
<td>CRE</td>
<td>Intervention 50; control NA</td>
<td>Incidence of infection</td>
<td>6 months after EoT</td>
<td>36%</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Zuckerman, 2011 [57]</td>
<td>CRE</td>
<td>Intervention 15; control NA</td>
<td>All-cause mortality</td>
<td>EoT</td>
<td>30%</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Lambelet, 2017 [58]</td>
<td>CRE</td>
<td>Intervention 14; control NA</td>
<td>All-cause mortality</td>
<td>EoT</td>
<td>40%</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Hseih, 2014 [70]</td>
<td>CRAB</td>
<td>Intervention 39; control NA</td>
<td>All-cause mortality</td>
<td>EoT</td>
<td>53%</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>Hseih, 2014 [70]</td>
<td>CRAB</td>
<td>Intervention 6; control NA</td>
<td>All-cause mortality</td>
<td>EoT</td>
<td>17%</td>
<td>NA</td>
<td>NA</td>
</tr>
</tbody>
</table>

Abbreviations: aHR, adjust hazard ratio; CRAB, carbapenem-resistant Acinetobacter baumannii; CRE, carbapenem-resistant Enterobacteriaceae; ESBL, extended-spectrum β-lactamase; EoT, end of treatment; NA, not applicable; NS, not significant; 3GcephRE, third-generation cephalosporin-resistant Enterobacteriaceae.

### Epidemiological outcomes

None of the studies evaluated epidemiological outcome.

### Adverse events

Resistance development was assessed in one RCT [51], three controlled studies [53–55] and all studies without comparator [56–61]. Among controlled studies, an increase in secondary resistance to decolonizing agents was reported in three studies [53–55]. Machuca et al. found that a significantly higher proportion of patients undergoing decolonization had gentamicin-resistant isolates in follow-up cultures than those not treated (13% (6/44) versus 3% (1/33); p = 0.008) [55]. In the Oren et al. and Lubbert et al. studies, 14% (7/50) and 28% (4/14) of patients, respectively, developed secondary resistance to decolonizing agents [53,54]. Saidel-Odes et al. did not observe increased resistance in their RCT [51]. None of the controlled studies reported a higher adverse event incidence in the intervention group.

### Evidence evaluation

Evidence was of low certainty for microbiological eradication at 1 week [51] and 6 months [55] post-treatment and CRE infection incidence at 6 months [55], and of very low certainty for microbiological eradication at 4 weeks [51] and all-cause mortality [55].

### Recommendation

The panel does not recommend routine decolonization of CRE.

Grading: conditional recommendation against the intervention.

### Research and possibly conditional use in restricted trials

On the basis of the limited evidence of increased risk of developing CRE infections in the colonized ICU population [12,13,62,63] and the results of the effectiveness of decolonization on CRE carriers [51,53], the panel suggests designing good-quality clinical studies to assess CRE infection risk in colonized haematological patients and solid organ transplant recipients. The panel further suggests using the results of these trials to design decolonization trials with oral colistin sulphate (80 mg (salt) four times daily) to temporarily suppress CRE carriage in high-risk patients. These trials should include careful monitoring of development of resistance to gentamicin and colistin during decolonization using stool cultures and antimicrobial susceptibility results according to the EUCAST clinical breakpoints [50].

### Fluoroquinolone-resistant Enterobacteriaceae

#### Study characteristics

Tannock et al. conducted a multicentre RCT in New Zealand to evaluate the efficacy of the probiotic strain *Escherichia coli* Nissle 1917 on FQRE colonization [64]. Sixty-nine elderly residents in long-term care facilities excreting norfloxacin-resistant *E. coli* were randomized to receive either probiotic (5 × 109 to 5 × 1011 bacteria daily, one capsule twice daily) or placebo for 5 weeks. Rectal and urinary carriage testing were assessed in the trial.

#### Clinical outcomes

No clinical outcome was assessed.

#### Microbiological outcomes

No significant difference was found in decolonization rate between the control and treated groups at 5 weeks post-treatment.

#### Epidemiological outcomes

No epidemiological outcome was analysed.
**Evidence evaluation**
Evidence was of low certainty for microbiological eradication at 5 weeks post-treatment.

**Recommendation**
Evidence is insufficient to provide a recommendation for or against any intervention.

**Aminoglycoside-resistant Enterobacteriaceae**

**Study characteristics**
The Oostdijk et al. study [42] is described above in the 3GcephRE section.

**Clinical outcomes**
Median length of ICU stay was 11.5 days (range 4–82; IQR 9.5) for ACRE-colonized patients and 12 days (range, 4–82; IQR 8) for decolonized patients.

**Microbiological outcomes**
The eradication rate was 62% (31/50) after a median of 5.5 days (IQR 3–60 days) of decolonization.

**Epidemiological outcomes**
No epidemiological outcome was analysed.

**Adverse events**
No adverse event was evaluated.

**Clinical outcomes**
Three case–control studies [66–68], one prospective cohort study [65], and one uncontrolled study [70] assessed clinical outcomes (all-cause mortality and infection rate). No significant difference in all-cause mortality during ICU stay was observed after oral decolonization [66]. All-cause mortality was assessed in two case-control studies comparing inhaled colistin with standard care, and no significant differences in mortality was observed [67,68]. Only Borer et al. observed a significant reduction in CRAB bloodstream infections after the intervention (0.6% versus 4.65%; p < 0.001) [65].

**Microbiological outcomes**
Three studies evaluated eradication rate [66–68]. Persistent CRAB carriage 14 days after treatment was assessed in two controlled studies. Chen et al. observed 14-day eradication in 54.3% of patients receiving decolonization versus 29.6% of controls (p 0.005), although a significant association was not observed for 28-day eradication rates (66.7% versus 51.9%; p 0.084) [67]. Kuo et al. observed a significant 14-day eradication rate (84.6% versus 10.3%; p < 0.001) [68]. Agusti et al. found significant reduction in faecal (48% versus 91%; p 0.001) and pharyngeal (38% versus 78%; p 0.03) carriage at discharge in patients who received SDD compared with controls. SDD did not affect cutaneous carriage [66].

**Epidemiological outcomes**
No epidemiological outcome was analysed.

**Adverse events**
No increased resistance overtime was seen when eradication failed.

**Recommendation**
Evidence is insufficient to provide a recommendation for or against any intervention.

**Carbapenem-resistant Acinetobacter baumannii**

**Study characteristics**
Three studies were performed in Taiwan and one each in Canada, Spain and Israel: one prospective cohort study [65], three case–control studies [66–68] and two case series without comparators [69,70]. All studies had a single-centre design. Four studies evaluated hospital patients [67–70] and two studied ICU patients [65,66]. Two studies were performed during a CRAB outbreak [66,69], one study was performed in a centre where CRAB was endemic [65], and three studies did not specify local epidemiology [66,68,70]. Respiratory tract cultures were performed in three studies [67,68,70], skin cultures in three studies [65,66,69], and rectal screening in two studies [66,69].

Borer et al. prospectively evaluated the impact of daily 4% chlorhexidine body wash in a cohort of 320 ICU patients [65]. Two controlled [67,68] studies and one case series [70] compared inhaled colistin (160 mg twice daily) with variable duration (7.3–13.5 days) to standard care in hospital patients. One controlled study [65] and one uncontrolled study [69] evaluated topical chlorhexidine during hospitalization. In one case–control study 21 ICU patients receiving an SDD regimen of colistin sulphate (50 mg (salt) four times daily) and tobramycin (80 mg four times daily) were compared to 33 ICU patients receiving standard care until discharge [66]. Gray et al. described the management of a CRAB ICU outbreak involving 29 patients using a multimodal intervention including 2% chlorhexidine washes; in this case series none of the outcomes evaluated in this systematic review were assessed [69].

**Evidence evaluation**
Evidence was of very low certainty for all the assessed outcomes.

**Recommendation**
Evidence is insufficient to provide a recommendation for or against any intervention.

**Faecal microbiota transplantation**
Faecal microbiota transplantation is the administration of thoroughly screened, healthy-donor stool into a patient’s gut, either into the colon (via enema or colonoscope) or into the upper small intestine (via nasojejunal tube or swallowed capsules) [71]. The potential benefit of FMT as an MDR-GNB decolonization strategy has been tested in nine uncontrolled studies with a high level of heterogeneity [72–80].

A single-centre study by Bilinski et al. investigated the use of FMT for MDR-GNB eradication in patients with haematological disorders [72]. Twenty-five FMTs were performed in 20 patients with intestinal MDR-GNB colonization, mainly carbapenemase- or ESBL-producing Enterobacteriaceae. Complete decolonization was achieved in 60% (15/25) of the cases at 1 month and in 13/14 (93%) of cases at 6 months post-treatment. Antibiotic use within 7 days post-treatment hampered the effectiveness of the intervention. Davido et al. reported the results of a series of eight FMTs, of which six were performed in patients colonized with carbapenemase-producing Enterobacteriaceae [73]. Eradication was obtained in two patients at 1 month post-treatment. No relapse of
colony was detected through 3 months of follow up. Table 4 provides details of study design and results.

**Recommendation**

Evidence is insufficient to provide a recommendation for or against FMT. Further studies are warranted to evaluate the effectiveness, applicability, and safety of FMT to confirm its role in intestinal decolonization of MDR-GNB.

**Limitations of the evidence and future research**

Our systematic review has identified important gaps in the literature on targeted decolonization strategies in MDR-GNB carriers. Studies have been evaluated for only a few clinically relevant MDR-GNB in specific settings, and, of those assessed, data are insufficient to provide robust recommendations on decolonization. High heterogeneity was detected among studies and did not allow any meta-analytic approach but only a qualitative review. The panel identified the following major flaws in the evaluated evidence: inconsistent reporting, small sample size, key outcomes not assessed, inconsistent effectiveness definition, colistin susceptibility testing not in accordance with current recommendations, and wide heterogeneity between settings (outbreak, endemic), decolonization regimens and treatment duration. The assessment typically evaluated a single intervention although multiple infection control measures are often implemented together as a bundle in clinical practice.

Because of the lack of effective drugs for MDR-GNB, the development of novel decolonization strategies through well-designed in vitro and in vivo studies is urgently needed [81]. These strategies may include natural compounds (FMT, prebiotics, probiotics), alternative therapies (tea tree oil, photodynamic therapies, omigan pentahydrochloride), and bacteriophage therapy. Well-designed multicentre RCTs are required to determine the impact of decolonization strategies on microbiological, epidemiological and clinical outcomes and development of resistance. Furthermore, the studies should evaluate the optimal dosing, duration, target populations and setting (endemic versus outbreak), and cost-effectiveness. Sequential interventions (e.g. oral SDD followed by FMT) should be explored. Evaluation of the efficacy of multimodal decolonization methods in stepped-wedge cluster RCTs should also be considered. Metagenomic studies assessing the effect of decolonizing agents on the microbiota composition and dynamics could provide valuable evidence for designing RCTs and drive choices of old and new drugs to be tested. Although it is understandable that research to date has focused on organisms with current significant clinical impact (3GcephRE, CRE, CRAB), we should not neglect other MDR-GNB (e.g. extremely drug-resistant *Pseudomonas aeruginosa*, pan-drug-resistant Gram-negative organisms) for which current experience is low but is likely to increase in the future.

**Key points**

- The panel does not recommend routine decolonization of MDR-GNB carriers.
- The effectiveness and long-term side effects of decolonization of 3GcephRE and CRE in high-risk populations (e.g. ICU, neutropenic and transplant populations) needs to be evaluated with RCTs with proper design and sample size calculation.

**Transparency declaration**

ET, FM, AMD, DB, BDH, EJK, JCL, NTM, MJS, Maria Souli, JTC, JRP declared no conflicts of interest. PE has witnessed advisory and consultancy roles at Abionic, 3M, Pfizer and received research support from 3M. Maurizio Sanguinetti received research support from Recordati, Pfizer and Menarini s.p.a. JRB participated in accredited educational activities supported by Merck through unrestricted grants and was coordinator of a drug-unrelated research project funded by AstraZeneca.

**Funding**

References


[29] Cochrane Effective Practice and Organisation of Care (EPOC). What study designs can be considered for inclusion in an EPOC review and what should they be called? EPOC resources for review authors. 2017. Available at: epoc.cochrane.org/epoc-resources-review-authors.


